Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 7, Issue 4, Pages 351-356Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.6b00005
Keywords
PI3K; kinase inhibitor; blood-brain barrier penetration; CNS; oncology
Categories
Ask authors/readers for more resources
Inhibition of phosphoinositide 3-kinase (PI3K) signaling is an appealing approach to treat brain tumors, especially glioblastoma multiforme (GBM). We previously disclosed our successful approach to prospectively design potent and blood brain barrier (BBB) penetrating PI3K inhibitors. The previously disclosed molecules were ultimately deemed not suitable for clinical development due to projected poor metabolic stability in humans. We, therefore, extended our studies to identify a BBB penetrating inhibitor of PI3K that was also projected to be metabolically stable in human. These efforts required identification of a distinct scaffold for PI3K inhibitors relative to our previous efforts and ultimately resulted in the identification of GDC-0084 (16). The discovery and preclinical characterization of this molecule are described within.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available